Latest findings indicate intravitreal injection regimens associated with treating retinal disease can have a detrimental effect on a patient’s quality of life.
Data showed 64 per cent of patients who undergo monthly eye injections wished the frequency of injections or appointments could be reduced.
The research, sponsored by drug firm Allergan, was presented last weekend at the 6th World Congress on Controversies in Ophthalmology in Sorrento, Italy, by Sobha Sivraprasad from Moorfields Eye Hospital.
Market research was conducted among 131 patients with either retinal vein occlusion or diabetic macular oedema in Germany, Italy and the UK.
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here